Sabre Partners leads $8 million Series B investment in Vyome Biosciences
Vyome recently successfully completed clinical studies on VB001 and VB2421 for mild to moderate dandruff
Recover your password.
A password will be e-mailed to you.
- Advertisement -
- Advertisement -
Recover your password.
A password will be e-mailed to you.